BS_J8G4SH4Z
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 38.64
- os_event
- false
- age_years
- 12.605
- sex
- M
- race
- African American
- new_clusters
- C6
- umap1_2d
- 2.845642357
- umap2_2d
- 6.225838788
- umap1_3d
- 2.140166363
- umap2_3d
- -1.002315756
- umap3_3d
- -4.671626354
- dataset
- Med-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.450
- DNA_REPAIR+0.320
- OXIDATIVE_PHOSPHORYLATION+0.200
- PI3K_AKT_MTOR_SIGNALING+0.170
- MITOTIC_SPINDLE+0.160
- HEME_METABOLISM+0.140
- ADIPOGENESIS+0.100
- E2F_TARGETS+0.090
- G2M_CHECKPOINT+0.080
- MYC_TARGETS_V1+0.080
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.490
- INTERFERON_ALPHA_RESPONSE-0.490
- INFLAMMATORY_RESPONSE-0.470
- ANGIOGENESIS-0.460
- ALLOGRAFT_REJECTION-0.450
- INTERFERON_GAMMA_RESPONSE-0.430
- APICAL_SURFACE-0.420
- COAGULATION-0.400
- MYC_TARGETS_V2-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2041 | Med | Medulloblastoma | 0.939 |
| 2 | MDT-AP-0395 | Med | Medulloblastoma | 0.931 |
| 3 | MDT-AP-0382 | Med | Medulloblastoma | 0.923 |
| 4 | MDT-AP-0113 | Med | Medulloblastoma | 0.922 |
| 5 | MDT-AP-3207 | Med | Medulloblastoma | 0.912 |
| 6 | SRR660812 | GTEX | — | 0.898 |
| 7 | BS_4CP4T22V | Med | Medulloblastoma | 0.897 |
| 8 | MDT-AP-0119 | Med | Medulloblastoma | 0.893 |
| 9 | MDT-AP-0722 | Med | Medulloblastoma | 0.891 |
| 10 | SRR819999 | GTEX | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.090 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.080 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.080 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.050 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.010 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.010 | Idelalisib | — uncovered |